NCT04053803View on ClinicalTrials.gov

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 22, 2019

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Sickle Cell Disease
Interventions
DRUG

IMR-687

Oral administration of once daily IMR-687

Trial Locations (7)

33021

Foundation for Sickle Cell Disease Research, Hollywood

76508

Baylor Scott & White Medical Center - Temple, Temple

06030

University of Connecticut Health Center, Farmington

Unknown

Bristol Haematology and Oncology Centre, Bristol

Guy's and St Thomas Hospital CRF, London

Royal London Hospital, London

NW1 2PG

University College London Hospital NHS Foundation Trust, London

All Listed Sponsors
lead

Imara, Inc.

INDUSTRY

NCT04053803 - An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia | Biotech Hunter | Biotech Hunter